Cargando…

Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis

OBJECTIVE: To assess in an observational study whether serum peptide antibody reactivities may distinguish aquaporin-4 (AQP4) antibody (Ab)–positive and -negative neuromyelitis optica spectrum disorders (NMOSD) and relapsing-remitting multiple sclerosis (RRMS). METHODS: We screened 8,700 peptides th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metz, Imke, Beißbarth, Tim, Ellenberger, David, Pache, Florence, Stork, Lidia, Ringelstein, Marius, Aktas, Orhan, Jarius, Sven, Wildemann, Brigitte, Dihazi, Hassan, Friede, Tim, Brück, Wolfgang, Ruprecht, Klemens, Paul, Friedemann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747481/ https://www.ncbi.nlm.nih.gov/pubmed/26894206 http://dx.doi.org/10.1212/NXI.0000000000000204

Ejemplares similares

Olfactory Dysfunction in Patients with Neuromyelitis Optica
por: Schmidt, Felix, et al.
Publicado: (2013)

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
por: Trebst, Corinna, et al.
Publicado: (2013)

The history of neuromyelitis optica
por: Jarius, Sven, et al.
Publicado: (2013)

Antibody signatures in patients with histopathologically defined multiple sclerosis patterns
por: Stork, Lidia, et al.
Publicado: (2020)

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
por: Stellmann, Jan-Patrick, et al.
Publicado: (2017)

Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate
por: Jarius, Sven, et al.
Publicado: (2014)

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
por: Jarius, Sven, et al.
Publicado: (2023)

Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance
por: Jarius, Sven, et al.
Publicado: (2010)

Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis
por: Schneider, Elisa, et al.
Publicado: (2013)

Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
por: Krumbholz, Markus, et al.
Publicado: (2015)

The history of neuromyelitis optica. Part 2: ‘Spinal amaurosis’, or how it all began
por: Jarius, S., et al.
Publicado: (2019)

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder
por: Chavarro, Velina S., et al.
Publicado: (2016)

Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder
por: Thöne, Jan, et al.
Publicado: (2018)

Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab
por: Harmel, Jens, et al.
Publicado: (2014)

MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T
por: Sinnecker, Tim, et al.
Publicado: (2016)

Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica
por: Paul, Friedemann, et al.
Publicado: (2007)

Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica
por: Pasquier, Baptiste, et al.
Publicado: (2019)

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
por: Jarius, Sven, et al.
Publicado: (2012)

Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis
por: Keller, Andreas, et al.
Publicado: (2015)

Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody–Seropositive Patients
por: Ayzenberg, Ilya, et al.
Publicado: (2021)

Optic chiasm measurements may be useful markers of anterior optic pathway degeneration in neuromyelitis optica spectrum disorders
por: Juenger, Valentin, et al.
Publicado: (2020)

Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study
por: Schmidt, Felix A., et al.
Publicado: (2020)

Structure–function correlates of vision loss in neuromyelitis optica spectrum disorders
por: Gigengack, Norman K., et al.
Publicado: (2022)

Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)
por: Hümmert, Martin W, et al.
Publicado: (2023)

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders
por: Ringelstein, Marius, et al.
Publicado: (2021)

Imaging the Visual Pathway in Neuromyelitis Optica
por: Pfueller, Caspar F., et al.
Publicado: (2011)

Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2018)

Update on biomarkers in neuromyelitis optica
por: Melamed, Esther, et al.
Publicado: (2015)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
por: Waters, Patrick, et al.
Publicado: (2016)

Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
por: Cree, Bruce AC, et al.
Publicado: (2015)

Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis
por: Jarius, S., et al.
Publicado: (2017)

Neuromyelitis Optica
por: Misra, M. C., et al.
Publicado: (1953)

Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Schindler, Patrick, et al.
Publicado: (2021)

Retinal Optical Coherence Tomography in Neuromyelitis Optica
por: Oertel, Frederike Cosima, et al.
Publicado: (2021)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Imaging markers of disability in aquaporin-4 immunoglobulin G seropositive neuromyelitis optica: a graph theory study
por: Chien, Claudia, et al.
Publicado: (2019)

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients
por: Pache, Florence, et al.
Publicado: (2016)

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
por: Jarius, S., et al.
Publicado: (2008)

Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study
por: Bove, Riley, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e1tfm0deb0tjkfj9n8tnjj5amr